The Dublin Consensus Statement on vital issues relating to the collection of blood and plasma and the manufacture of plasma products.

摘要

The requirement for plasma products manufactured from both source and recovered plasma for the treatment of many medical conditions is projected to increase substantially in the course of the next 5 years [1]. Patient organizations representing many thousands of patients with rare disorders who are dependant on products manufactured from plasma formed a coalition of plasma users- PLUS- in 2009. PLUS represents the concerted views of seven organisations, the International Patients Organisation for Primary Immunodeficiency (IPOPI), the World Federation of Hemophilia (WFH), the European Haemophilia Consortium (EHC), Alfa Europe, Idiopathic Thrombocytopenic Purpura Support Organisation (ITP), Hereditary Angiodema International (HAEI) and Guillain Barre Syndrome Foundation International (GBS/CIDP).